Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: I am still considering the transmutation of share pricing’s value

April 4, 2019 7:29am

News: Homology Medicines (FIXX), a genetic medicines company, announced today that the U.S. FDA has provided clearance for Homology to begin its P1/2 pheNIX clinical trial with HMI-102, a one-time gene therapy candidate for adults with the rare genetic disease phenylketonuria (PKU), an inborn error of metabolism.

Financing: Pluristem (PSTI) offering pricing still has not been revealed – transparency question?

Last night I stated, “Build cash positions and “powder” for the coming counter-cycle; it’s not a dig at the sector but, by being tactical - don’t disturb liquidity to enhance portfolio protection”

Pre-open indications: 3 BUY, 4 SELLs and 3 TRADES

You’d be reading if you were a subscriber!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.